Immunovant Inc
IMVTHealthcare|Biotechnology|USA
$39.71
-1.38 (-3.36%)
Tangible Book
$4.18
Earnings Power
$4.41
Clinical Trials (19)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07039916 Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis | Generalized Myasthenia Gravis | P3 | Recruiting | 231 | RCT, Double-blind | IMVT-1402, IMVT-1402, Placebo, IMVT-1402 |
| NCT05403541 Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis | Generalized Myasthenia Gravis | P3 | Active | 240 | RCT, Double-blind | Batoclimab 680 mg SC weekly, Batoclimab 340 mg SC weekly, Matching Placebo SC, Batoclimab 340 mg SC bi-weekly |
| NCT06980805 A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE) | Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus | P2 | Active | 56 | RCT, Double-blind | IMVT-1402, Placebo |
| NCT05581199 To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP | Chronic Inflammatory Demyelinating Polyneuropathy | P2 | Active | 277 | RCT, Double-blind | Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly, Batoclimab 340 mg SC weekly, Placebo |
| NCT07018323 A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease | Graves' Disease | P2 | Recruiting | 210 | RCT, Double-blind | IMVT-1402, IMVT-1402, Placebo |
| NCT06727604 A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease | Graves' Disease | P2 | Recruiting | 240 | RCT, Double-blind | IMVT-1402, IMVT-1402, Placebo |
| NCT06754462 A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis | Rheumatoid Arthritis | P2 | Active | 120 | RCT, Double-blind | IMVT-1402, Placebo |
| NCT07032662 Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Chronic Inflammatory Demyelinating Polyneuropathy | P2 | Recruiting | 162 | RCT, Double-blind | Imeroprubart, Placebo |
| NCT06979531 Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity | Primary Sjögren's Syndrome | P2 | Recruiting | 180 | RCT, Double-blind | IMVT-1402, Placebo |
| NCT05517421 Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease | Thyroid Eye Disease | P3 | Completed | 114 | RCT, Double-blind | Batoclimab, Placebo |
| NCT05524571 Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease | Thyroid Eye Disease | P3 | Completed | 86 | RCT, Double-blind | Batoclimab, Placebo |
| NCT05517447 Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease | Thyroid Eye Disease | P3 | Terminated | 109 | Open-label | Batoclimab |
| NCT03863080 A Study of RVT-1401 in Myasthenia Gravis (MG) Patients | Myasthenia Gravis | P2 | Completed | 17 | RCT, Double-blind | RVT-1401, Placebo |
| NCT03922321 Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO) | Graves' Ophthalmopathy | P2 | Completed | 7 | Open-label | RVT-1401 |
| NCT07188844 An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Chronic Inflammatory Demyelinating Polyneuropathy | P2 | By Invite | 108 | Open-label | Batoclimab |
| NCT03938545 ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO ) | Graves' Ophthalmopathy (GO) | P2 | Terminated | 65 | RCT, Double-blind | RVT-1401 (Administered via subcutaneous injection) |
| NCT05907668 A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease | Graves Disease | P2 | Completed | 35 | Open-label | IMVT-1401 (batoclimab) |
| NCT04253236 To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA). | Warm Autoimmune Hemolytic Anemia | P2 | Terminated | 5 | Open-label | RVT-1401 680 mg/weekly, RVT-1401 340 mg/weekly |
| NCT07286006 A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD) | Graves' Disease | P2 | By Invite | 372 | Open-label | IMVT-1402 |